albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-06. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
=== Self-healing materials === For materials such as components in microelectronics, polymeric coatings, and adhesives, nanocapsules can reduce damage caused by high loads. The healing of cracks within these materials is alleviated by dispersing nanocapsules within the polymer. The healing substances include dicyclopentadiene (DCPD), which is prepared on site within the material by sonication. The nanoencapsulated material is first emulsified within the host material by creating an oil-in-water self-healing epoxy. The emulsified material is then agitated within the host material to form particles which then bond to the host material.
== Function == IDE was first identified by its ability to degrade the B chain of the hormone insulin. This activity was observed over sixty years ago, though the enzyme specifically responsible for B chain cleavage was identified more recently. This discovery revealed considerable amino acid sequence similarity between IDE and the previously characterized bacterial protease pitrilysin, suggesting a common proteolytic mechanism. IDE, which migrates at 110 kDa during gel electrophoresis under denaturing conditions, has since been shown to have additional substrates, including the signaling peptides glucagon, TGF alpha, and β-endorphin. In addition, IDE may have an important function in the retinal function due to its high expression in the outer segment of cones.
Aldosterone is the main mineralocorticoid steroid hormone produced by the zona glomerulosa of the adrenal cortex in the adrenal gland. It is essential for sodium conservation in the kidney, salivary glands, sweat glands, and colon. It plays a central role in the homeostatic regulation of blood pressure, plasma sodium (Na+), and potassium (K+) levels. It does so primarily by acting on the mineralocorticoid receptors in the distal tubules and collecting ducts of the nephron. It influences the reabsorption of sodium and excretion of potassium (from and into the tubular fluids, respectively) of the kidney, thereby indirectly influencing water retention or loss, blood pressure, and blood volume. When dysregulated, aldosterone is pathogenic and contributes to the development and progression of cardiovascular and kidney disease. Aldosterone has exactly the opposite function of the atrial natriuretic hormone secreted by the heart. Aldosterone is part of the renin–angiotensin–aldosterone system. It has a plasma half-life of less than 20 minutes. Drugs that interfere with the secretion or action of aldosterone are in use as antihypertensives, like lisinopril, which lowers blood pressure by blocking the angiotensin-converting enzyme (ACE), leading to lower aldosterone secretion. The net effect of these drugs is to reduce sodium and water retention but increase the retention of potassium. In other words, these drugs stimulate the excretion of sodium and water in urine, while they block the excretion of potassium.
=== DSF-GTP === The DSF-GTP (GFP-Tagged Protein-of-Interest) technique was developed by a team led by Patrick Schaeffer at James Cook University and published in Moreau et al. 2012. The development of differential scanning fluorimetry and the high-throughput capability of Thermofluor have vastly facilitated the screening of crystallization conditions of proteins and large mutant libraries in structural genomics programs, as well as ligands in drug discovery and functional genomics programs. These techniques are limited by their requirement for both highly purified proteins and solvatochromic dyes, prompting the need for more robust high-throughput technologies that can be used with crude protein samples. This need was met with the development of a new high-throughput technology for the quantitative determination of protein stability and ligand binding by differential scanning fluorimetry of proteins tagged with green fluorescent protein (GFP). This technology is based on the principle that a change in the proximal environment of GFP, such as unfolding and aggregation of the protein of interest, is measurable through its effect on the fluorescence of the fluorophore. The technology is simple, fast and insensitive to variations in sample volumes, and the useful temperature and pH range is 30–80 °C and 5–11 respectively. The system does not require solvatochromic dyes, reducing the risk of interferences. The protein samples are simply mixed with the test conditions in a 96-well plate and subjected to a melt-curve protocol using a real-time thermal cycler.
Sources: en.wikipedia.org
== Side effects == Adverse effects of vinblastine include hair loss, loss of white blood cells and blood platelets, gastrointestinal problems, high blood pressure, excessive sweating, depression, muscle cramps, vertigo and headaches. As a vesicant, vinblastine can cause extensive tissue damage and blistering if it escapes from the vein from improper administration.
A number of Neanderthal fossils had been discovered before their antiquity was fully understood. The first Neanderthal remains—Engis 2 (a skull)—were discovered in 1829 by Dutch/Belgian prehistorian Philippe-Charles Schmerling in the Grottes d'Engis, Belgium. He concluded that these "poorly developed" human remains must have been buried at the same time and by the same causes as the co-existing remains of extinct animal species. In 1848, Gibraltar 1 from Forbes' Quarry was presented to the Gibraltar Scientific Society by their Secretary Lieutenant Edmund Henry Réné Flint, but was thought to be a modern human skull. In 1856, local schoolteacher Johann Carl Fuhlrott recognised bones from Kleine Feldhofer Grotte in Neander Valley—Neanderthal 1—as distinct from modern humans, and gave them to German anthropologist Hermann Schaaffhausen to study in 1857. It comprised the cranium, thigh bones, right arm, left humerus and ulna, left ilium (hip bone), part of the right shoulder blade, and pieces of the ribs.
==== Fruiting and dispersal ==== After fertilization, one or both ovules develop into fruit-like structures containing seeds. The fruits are 1.5–2 cm (5⁄8–3⁄4 in) long, with a soft, fleshy, yellow-brown outer layer (the sarcotesta) that is attractive in appearance, but contains butyric acid (also known as butanoic acid) and smells foul like rancid butter or vomit when fallen. Ginkgo seed stalks are as long as its leaf stalks, with 1–2 seeds at their tips. Ripe seeds shed with autumn leaves, or may persist a little longer. Beneath the sarcotesta is the hard sclerotesta (the "shell" of the seed) and a papery endotesta, with the nucellus surrounding the female gametophyte at the center. Despite its perception by humans as foul, the fruit odor is attractive to certain small mammals that eat the fruit and disperse the seeds: these include the gray squirrel and, in East Asia, the palm civet and raccoon dog. The sclerotesta resists digestion, and so the seeds are passed intact into feces, which thus provide a dispersal mechanism.
=== Interoception === Interoception involves the conscious and unconscious sense of the internal state of the body, having an important role in homeostasis and regulation of emotions. Aside from noticeable physiological dysfunction, interoceptive deficits also prompt individuals with anorexia to concentrate on distorted perceptions of multiple elements of their body image. This exists in both people with anorexia and in healthy individuals due to impairment in interoceptive sensitivity and interoceptive awareness. Aside from weight loss and outer appearance, people with anorexia also report abnormal bodily functions such as indistinct feelings of fullness. This is due to miscommunication between internal signals of the body and the brain. Due to impaired interoceptive sensitivity, powerful cues of fullness may be detected prematurely in highly sensitive individuals, which add to decreased calorie consumption and generate anxiety surrounding food intake in anorexia patients. People with anorexia also report difficulty identifying and describing their emotional feelings and the inability to distinguish emotions from bodily sensations in general, called alexithymia: again, likely due to the miscommunication of signals within the body. Interoceptive awareness and emotion are deeply intertwined. Anorexia patients also exhibit emotional regulation difficulties that ignite emotionally cued eating behaviors, such as restricting food or excessive exercising.
=== Impacts of gender stereotypes in health and medicine === Gender stereotypes influence both diagnosis and treatment practices for men and women. Ancient theories, such as those of Hippocrates, perpetuated hierarchical models in which the female body was considered a deviation from the male norm—a view that persisted into the 19th century. Some diseases are underdiagnosed in one sex due to stereotypical associations. For instance, women are less frequently and less accurately diagnosed with myocardial infarction, despite an increase in incidence among women between 2008 and 2013 (+20%). Symptoms in women may differ from those in men and are less well-known or recognized. In 2015, cardiovascular disease accounted for 51% of deaths in women in Europe. Similar disparities exist in other conditions. Women with chronic obstructive pulmonary disease (COPD) are diagnosed later than men, even though prevalence is now similar. Women with autism spectrum disorders are often diagnosed late, which has been linked to significantly reduced life expectancy compared to non-autistic women. Strokes, more common among women, also have more severe outcomes in women but were less studied in female patients as of 2017. Conversely, some conditions such as osteoporosis are underdiagnosed in men, as the disease is often seen as predominantly affecting women. Despite this, men represent one-third of hip fractures and have a higher risk of complications.
Sources: en.wikipedia.org
== People who were affected with dermatomyositis == Opera singer Maria Callas (1923–1977) allegedly had dermatomyositis from 1975 until her death. Actor Laurence Olivier (1907–1989) had dermatomyositis from 1974 until his death. American football running back Ricky Bell (1955–1984), the runner-up for the Heisman Trophy in 1976, and the number-one pick in the NFL draft in 1977, died at the age of 29 from heart failure caused by this disease. Rob Buckman (1948–2011) a doctor, comedian, and author, and the president of the Humanist Association of Canada. Samantha, Indian actress diagnosed in 2022. Suhani Bhatnagar (2005–2024), Indian actress. Tim Rooney (1947–2006), American actor and son of Mickey Rooney.
Other common symptoms which come on rapidly include neuromuscular symptoms, shock, loss of consciousness, hypotension, pallor, ataxia, excessive salivation (oral secretions may become profuse and thick), limb paralysis, nausea and vomiting, ptosis, fever, and severe abdominal pain. Local tissue damage appears to be relatively infrequent and of minor severity in most cases of black mamba envenomation. Edema is typically minimal. Acute kidney injury has been reported in a few cases of black mamba bites in humans as well as in animal models. Death is due to suffocation resulting from paralysis of the respiratory muscles. Untreated black mamba bites have a mortality rate of 100%. Antivenom therapy is the mainstay of treatment for black mamba envenomation. A polyvalent antivenom produced by the South African Institute for Medical Research (SAIMR) is used to treat all black mamba bites from different localities. Because of the availability of antivenom, a bite from a black mamba no longer results in certain death, but in order for the antivenom therapy to be successful, vigorous treatment and large doses of antivenom must be administered rapidly post-envenomation. In case studies of black mamba envenomation, respiratory paralysis has occurred in less than 15 minutes. Envenomation by this species invariably causes severe neurotoxicity because black mambas often strike repeatedly in a single lunge. The doses of antivenom required are often massive (10–30+ vials) for bites from this species.
On the night of 24/25 July 1261, Strategopoulos and his men approached the city walls and hid at a monastery near the Gate of the Spring. Strategopoulos sent a detachment of his men, led by some of the thelematarioi, to make their way to the city through a secret passage. This afforded them the opportunity to attack the walls from the inside, which surprised the guards and opened the gate, giving the Nicaean forces an entry into the city. The Latins were taken completely unaware, and after a short struggle, the Nicaeans gained control of the Theodosian land walls. As news of this spread across the city, the Latin inhabitants, from Emperor Baldwin II downwards, hurriedly rushed to the harbours of the Golden Horn, hoping to escape by ship. At the same time, Strategopoulos' men set fire to the Venetian buildings and warehouses along the coast to prevent them from landing there. Due to the timely arrival of the returning Venetian fleet, many of the Latins managed to evacuate to the still Latin-held parts of Greece, marking the end of the Latin occupation with the city's restoration to the Byzantines.
The 1960s and 1970s saw a great deal of activity (and expenditure) in the recovery of manganese nodules from the abyssal plains, with varying degrees of success. This does demonstrate, however, that the recovery of minerals from the seafloor is possible and has been possible for some time. Mining of manganese nodules served as a cover story for the elaborate attempt in 1974 by the CIA to raise the sunken Soviet submarine K-129 using the Glomar Explorer, a ship purpose-built for the task by Howard Hughes. The operation was known as Project Azorian, and the cover story of seafloor mining of manganese nodules may have served as the impetus to propel other companies to make the attempt.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.